Concordia International Corp. (CXRX) EPS Estimated At $0.06

March 3, 2018 - By Vivian Park

 Concordia International Corp. (CXRX) EPS Estimated At $0.06

Analysts expect Concordia International Corp. (NASDAQ:CXRX) to report $0.06 EPS on March, 21.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $0.06 EPS. CXRX’s profit would be $3.11 million giving it 2.75 P/E if the $0.06 EPS is correct. After having $0.06 EPS previously, Concordia International Corp.’s analysts see 0.00 % EPS growth. The stock increased 4.35% or $0.03 during the last trading session, reaching $0.66. About 60,780 shares traded. Concordia International Corp. (NASDAQ:CXRX) has declined 95.85% since March 3, 2017 and is downtrending. It has underperformed by 112.55% the S&P500.

Concordia International Corp. (NASDAQ:CXRX) Ratings Coverage

Among 9 analysts covering Concordia Healthcare Corp. (NASDAQ:CXRX), 4 have Buy rating, 2 Sell and 3 Hold. Therefore 44% are positive. Concordia Healthcare Corp. had 20 analyst reports since August 11, 2015 according to SRatingsIntel. On Thursday, August 4 the stock rating was downgraded by TD Securities to “Hold”. The company was maintained on Tuesday, August 11 by Canaccord Genuity. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Sell” rating given on Wednesday, August 9 by Canaccord Genuity. Laurentian maintained the stock with “Buy” rating in Tuesday, March 29 report. The stock of Concordia International Corp. (NASDAQ:CXRX) has “Outperform” rating given on Thursday, October 1 by RBC Capital Markets. The rating was downgraded by IBC on Monday, August 15 to “Underperformer”. The firm has “Sector Outperform” rating by Scotia Capital given on Friday, October 16. As per Monday, August 15, the company rating was downgraded by GMP Securities. Goldman Sachs maintained it with “Neutral” rating and $13 target in Monday, August 15 report. Mackie upgraded it to “Speculative Buy” rating and $42.50 target in Monday, October 19 report.

Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company has market cap of $34.24 million. It operates through three divisions: Concordia International, Concordia North America, and Orphan Drugs. It currently has negative earnings. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

More notable recent Concordia International Corp. (NASDAQ:CXRX) news were published by: which released: “Concordia International Corp. Announces New Communication With CMA” on October 11, 2017, also with their article: “Concordia International Corp. Comments on CMA’s Decision to Close its …” published on February 15, 2018, published: “Concordia International Corp. Announces Third Quarter 2017 Results” on November 14, 2017. More interesting news about Concordia International Corp. (NASDAQ:CXRX) were released by: and their article: “Concordia International Corp. Announces Release Date for Fourth Quarter and …” published on February 21, 2018 as well as‘s news article titled: “Concordia International Corp. Takes Next Step to Realign Its Capital Structure …” with publication date: October 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.